Breaking News
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% Upgrade now
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
61.69 -1.38    -2.19%
30/09 - Closed. Currency in USD ( Disclaimer )
After Hours
61.78
+0.09
+0.15%
30/09
  • Volume: 8,777,150
  • Bid/Ask: 61.70 / 62.02
  • Day's Range: 61.61 - 63.58
Type:  Equity
Market:  United States
Gilead 61.69 -1.38 -2.19%

GILD Recent Sentiments

 
This page features our users' sentiments regarding the Gilead share. Assess users' predictions on whether they expect Gilead shares to be bearish or bullish.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Sep 30, 2022 Сергей Алмаз   62.76 -1.70%
Sep 28, 2022 Vicent Sales   63.42 -2.73%
Sep 27, 2022 Carlos Pestana...   62.68 -1.58%
Sep 21, 2022 Marco Tagliani   65.31 Sep 26, 2022 @ 62.61 -4.13%
Sep 16, 2022 Wouter de Quelerij   65.28 Sep 19, 2022 @ 65.09 +0.29%
Sep 13, 2022 Jovica Palashevski   66.08 -6.64%
Sep 12, 2022 Javier Ruben   67.89 -9.13%
Sep 12, 2022 Peter Goodwin   68.31 -9.69%
Sep 12, 2022 Ivan Peretz   68.75 -10.27%
Sep 12, 2022 Gio Mal   68.14 -9.47%
Sep 07, 2022 Лёша Ахремчик   64.67 Sep 30, 2022 @ 61.69 -4.61%
Sep 06, 2022 Alex Kolesnikov   62.99 Sep 12, 2022 @ 68.24 +8.33%
Sep 06, 2022 Fabio Lombardi   63.35 Sep 30, 2022 @ 61.69 +2.62%
Sep 01, 2022 Alex Kolesnikov   64.41 Sep 05, 2022 @ 63.82 -0.92%
Aug 26, 2022 neal macdougall   62.81 Aug 29, 2022 @ 62.27 +0.86%
Aug 23, 2022 Luis Alejandro Pavón   63.89 Sep 16, 2022 @ 65.60 +2.68%
Aug 22, 2022 Alex Kolesnikov   64.71 Aug 29, 2022 @ 62.27 -3.77%
Aug 18, 2022 Marco Tagliani   64.76 Aug 22, 2022 @ 64.67 +0.14%
Aug 18, 2022 neal macdougall   64.98 Aug 22, 2022 @ 64.67 +0.48%
Aug 17, 2022 Abdulaziz Bajeel   66.63 Aug 22, 2022 @ 64.67 -2.94%
Aug 15, 2022 Gil Belkin   66.09 Sep 09, 2022 @ 65.28 -1.23%
Aug 15, 2022 Gio Mal   65.98 Sep 09, 2022 @ 65.28 -1.06%
Aug 15, 2022 Waldemar Patacz   65.89 Sep 09, 2022 @ 65.28 +0.93%
Aug 15, 2022 Antoni fermos   65.80 Sep 09, 2022 @ 65.28 -0.79%
Aug 15, 2022 Gerry Potter   65.74 Sep 09, 2022 @ 65.28 +0.70%
Aug 15, 2022 Alex Kolesnikov   65.61 Aug 22, 2022 @ 64.67 -1.43%
Aug 15, 2022 Michael Michael   65.77 Sep 09, 2022 @ 65.28 -0.75%
Aug 15, 2022 Fabio Lombardi   64.23 Aug 22, 2022 @ 64.67 +0.69%
Aug 12, 2022 Mateusz Mateoo   62.91 Sep 02, 2022 @ 63.82 +1.45%
Aug 12, 2022 Константин Во   62.88 Sep 02, 2022 @ 63.82 +1.49%
Aug 10, 2022 Ralph Lang   62.76 Sep 02, 2022 @ 63.82 -1.69%
Aug 05, 2022 Ana Maria Chirila   61.19 Aug 26, 2022 @ 62.37 +1.93%
Aug 03, 2022 Андрей Фёдоров   63.17 Aug 26, 2022 @ 62.37 -1.27%
Aug 03, 2022 Mark Giro   63.48 Aug 08, 2022 @ 61.35 -3.36%
Aug 02, 2022 Alex Kolesnikov   59.72 Aug 08, 2022 @ 61.35 +2.73%
Aug 01, 2022 Alex Fontaine   60.00 Aug 26, 2022 @ 62.37 +3.95%
Aug 01, 2022 Trieu Tranxuan   59.61 Aug 26, 2022 @ 62.37 +4.63%
Jul 29, 2022 James Maze   59.96 Aug 19, 2022 @ 65.34 +8.97%
Jul 27, 2022 Alex Kolesnikov   61.27 Aug 01, 2022 @ 59.91 -2.22%
Jul 25, 2022 Marco Tagliani   60.59 Aug 01, 2022 @ 59.91 -1.12%
Jul 22, 2022 Dmitry sokolov   60.77 Aug 13, 2022 @ 62.96 -3.60%
Jul 07, 2022 Alex Kolesnikov   62.74 Jul 11, 2022 @ 62.70 -0.06%
Jul 06, 2022 T O   62.67 Jul 29, 2022 @ 59.75 -4.66%
Jun 28, 2022 Francesco Marra   62.28 Jul 22, 2022 @ 60.80 +2.38%
Jun 24, 2022 Renee Cheung   62.04 Jul 15, 2022 @ 62.60 +0.90%
Jun 22, 2022 Данияр Темирбаев   61.62 Jul 15, 2022 @ 62.60 +1.59%
Jun 22, 2022 Dưỡng Đào Bá   61.80 Jun 27, 2022 @ 63.10 +2.10%
Jun 21, 2022 Gianluca Pellegrini   60.35 Jul 15, 2022 @ 62.60 +3.73%
Jun 17, 2022 Dưỡng Đào Bá   58.08 Jun 20, 2022 @ 58.53 +0.77%
Jun 16, 2022 Mr Jonas   57.46 Jul 08, 2022 @ 62.84 +9.36%
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
Chili Daug
Chili Daug May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when? hahah
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email